Lonquex Market Report 2026

Lonquex Market Overview

• The Lonquex market growth in the historic period has been driven by increasing use of chemotherapy treatments, advancements in hematology supportive care • Market expansion is supported by growing demand for long-acting supportive care drugs, rising biosimilar competition • Growth Driver: Rising Cancer Incidence Driving Growth Of The Lonquex Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Lonquex Market?

Lonquex refers to the medication lipegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of white blood cells. It is commonly prescribed to treat severe neutropenia, a condition characterized by an abnormally low level of neutrophils, which are essential for fighting infections. This condition often occurs in patients undergoing chemotherapy for cancer, as chemotherapy can suppress the bone marrow's ability to produce white blood cells. The main type of lonquex formulation are injectable formulation (solution for injection), pre-filled syringes or auto-injectors. Injectable formulation (solution for injection) refers to a liquid drug form that is administered directly into the body via injection. This method ensures rapid delivery and effective therapeutic results, particularly in hospital settings for conditions like neutropenia. The indication are prevention of chemotherapy-induced neutropenia, treatment of neutropenia in hematological malignancies and supportive care for chemotherapy. The patient demographics are adult patients, geriatric patients and pediatric patients. The distribution channel are direct sales, wholesalers and distributors, retail pharmacies and online pharmacies, and end users includes hospitals, oncology clinics, dermatology clinics and research institutions.

What Is The Lonquex Market Growth Forecast?

The growth in the forecast period can be attributed to growing demand for long-acting supportive care drugs, rising biosimilar competition, increasing cancer patient populations, expansion of outpatient oncology services, continued innovation in hematopoietic growth factors. Major trends in the forecast period include increasing adoption of long-acting g-csf therapies, rising focus on chemotherapy supportive care, growing preference for single-dose treatment regimens, expansion of biosimilar development programs, enhanced emphasis on infection risk reduction.

Global Lonquex Market Segmentation

1) By Indication: Prevention of Chemotherapy-Induced Neutropenia, Treatment of Neutropenia in Hematological Malignancies, Supportive Care for Chemotherapy 2) By Formulation: Injectable Formulation (Solution For Injection), Pre-Filled Syringes Or Auto-Injectors 3) By Patient Demographics: Adult Patients, Geriatric Patients, Pediatric Patients 4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies 5) By End User: Hospitals, Oncology Clinics, Dermatology Clinics, Research Institutions

What Are The Drivers Of The Lonquex Market?

The rising cancer incidence is expected to propel the growth of the lonquex market going forward. Cancer incidence refers to the number of new cases of cancer diagnosed in a specific population during a defined time period, usually expressed per 100,000 individuals per year. Rising cancer incidence is attributed to factors such as an aging population, lifestyle changes including increased tobacco and alcohol consumption, environmental exposure to carcinogens, genetic predispositions, and improved diagnostic capabilities. Lonquex (lipegfilgrastim) works to lower the risk of infection in cancer patients by enhancing the production of white blood cells, thus minimizing the effects of chemotherapy-induced neutropenia. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 35 million new cancer cases are projected for 2050, representing a 77% rise compared with the estimated 20 million cases reported in 2022. Therefore, the rising cancer incidence is driving growth of lonquex industry. The expansion of biosimilars is expected to propel the growth of the lonquex market going forward. Biosimilars refer to biologic medical products that are highly similar to an already approved reference biologic product, with no clinically meaningful differences in terms of safety, efficacy, or potency. The expansion of biosimilars is attributed to increasing healthcare cost containment efforts, patent expirations of biologic drugs, rising prevalence of chronic diseases, and growing acceptance of biosimilars among healthcare providers and patients. Lonquex (lipegfilgrastim) functions as a biosimilar by replicating the natural activity of granulocyte colony-stimulating factor (G-CSF), promoting neutrophil production and release from the bone marrow, thereby lowering infection risk in chemotherapy patients. For instance, in July 2025, according to the Abbott Laboratories, a US-based pharmaceutical company, biosimilars have helped European healthcare systems save over $64 billion to date. Therefore, the expansion of biosimilars is driving growth of lonquex industry.

Key Players In The Global Lonquex Market

Major companies operating in the lonquex market are Teva Pharmaceutical Industries Ltd

What Are Latest Mergers And Acquisitions In The Lonquex Market?

In August 2024, Lotus Pharmaceutical Co Ltd., a Taiwan-based pharmaceutical company, acquired Teva Pharma (Thailand) Co. Ltd for an undisclosed amount. The acquisition aims to expand Lotus Pharmaceuticals' footprint in Southeast Asia, enhance its oncology and women's health product offerings, and gain access to Teva's ophthalmic and respiratory portfolio. This strategic move will also bolster Lotus' presence in both hospital and pharmacy channels in Thailand. Teva Pharma (Thailand) Co. Ltd is a Thailand-based pharmaceuticals company that specializes in providing lonquex.

Regional Insights

North America was the largest region in the lonquex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Lonquex Market?

The lonquex market consists of sales of CAR T-cell therapy kits, granulocyte colony-stimulating factor (G-CSF) drugs, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lonquex Market Report 2026?

The lonquex market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lonquex industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.